Search Results
107 Results Found for “sudden cardiac death”
Prof. Jens Cosedis Nielsen discusses the DANISH-CRT trial, why targeted electrical mapping did not improve outcomes, and the questions that remain around the future of cardiac resynchronization therapy.
The first dedicated ESC Guidelines on the management of cardiovascular disease and chronic kidney disease recommend kidney function and urine albumin testing in all patients with cardiovascular disease, with an emphasis on identifying CKD early and initiating effective treatment without delay.
Native valve infective endocarditis (IE) is rare, with an incidence of 3–7 cases per 100,000 person-years.1,2 Cardiac structural complications from local infection extension include valvular destruction, peri-annular abscess and fistula formation. Left ventricular pseudoaneurysm (LVP) from IE is exceedingly rare, occurring in &...
At EHRA 2026, Professor Claudio Tondo presents his highlights on advances in ablation and device technologies, led by pulsed field ablation, showcasing a rapidly evolving landscape in the treatment of complex arrhythmias.
Ventricular fibrillation (VF) is characterized by rapid (>300 beats a per minute), irregular electrical activation with variable electrocardiographic waveforms that prevents coordinated myocardial contraction, resulting in immediate loss of cardiac output.1 It most commonly occurs in the context of coronary ...
Professor Amir Jadidi presented results from SOLVE-AF at EHRA 2026, showing that sinus rhythm–guided substrate ablation significantly improves outcomes in persistent AF patients with atrial fibrosis and supporting a more personalized ablation strategy.
Sudden cardiac arrest (SCA) in young adults (typically defined as individuals younger than 40 years) has emerged as an important yet under-recognized public health concern. Recent estimates suggest an incidence of approximately 1–4 cases per 100,000 person-years, underscoring the clinical and epidemiological relevance ...
At EHRA 2026, late-breaking trials across ablation, devices, and drug therapy signal major shifts in arrhythmia management, highlighting both rapid innovation and key unanswered questions. We spoke to Prof Jose Luis Merino for his highlights.
From EHRA 2026, Dr Salik Ur Rehman discusses advances in pulsed field ablation, mapping technologies, and conduction system pacing highlight a rapidly evolving landscape in electrophysiology care.
At EHRA 2026, Ben Petrazzini discussed new research that shows AI can improve identification of sudden cardiac death in electronic health records, enabling more accurate large-scale studies and advancing prevention strategies.
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
July 2025 marked continued progress in cardiovascular innovation, with notable regulatory decisions and clinical trial milestones. Approvals, designations, and data readouts during the month highlight the field’s ongoing shift toward targeted therapies, gene-based interventions, and outcome-driven evidence. These developments reflect growing momentum in addressing complex and underserved cardiovascular conditions.
In this interview, Dr Valentina Kutyifa, University of Rochester Medical Center, Rochester, NY, USA, offers insight into the BIO LIBRA study (ClinicalTrials.gov identifier: NCT03884608), a landmark trial designed to reassess outcomes in patients with non-ischaemic cardiomyopathy in the era of contemporary medical therapy. Recognizing that much of the original evidence supporting implantable cardioverter-defibrillator (ICD) use in this population dates back decades, the BIO LIBRA study was initiated to fill key knowledge gaps using modern treatment protocols.
In this interview, Dr Louise Olde Nordkamp, a device cardiologist at Amsterdam University Medical Center, discusses the long-term findings of the PRAETORIAN XL trial—a follow-up study comparing transvenous and subcutaneous implantable cardioverter-defibrillators (ICDs). Building on the original PRAETORIAN trial, this extended 8-year analysis evaluated device-related complications and confirmed that subcutaneous ICDs carry fewer major and lead-related complications. Dr Olde Nordkamp highlights the clinical relevance of these results, supporting broader consideration of subcutaneous ICDs in patients without pacing indications.
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac abnormality characterized by left ventricular hypertrophy and diastolic dysfunction, primarily attributed to mutations in genes that encode sarcomeric proteins.1,2 The disease manifests in two broad phenotypes: obstructive HCM (oHCM), defined by dynamic left ...
May 2025 saw several significant developments in the field of cardiology, including new regulatory approvals, long-term clinical trial data and important findings from late-breaking studies. This roundup highlights the latest updates across structural, interventional and heart failure therapies, with implications for ...
Visionary Voices: Season 1, Episode 7 Join us in this episode as Trudie Lobban, Founder and Trustee of Arrhythmia Alliance, discusses the remarkable work of Pace4Life. This innovative charity repurposes cardiac electronic devices, delivering critical heart care to communities in low- ...
Highlights The autonomic nervous system plays a critical role in the aetiopathogenesis of atrial fibrillation (AF). Neuromodulation of the autonomic nervous system has been a topic of increased interest in the management of AF. Ablation of ganglionated plexi, ethanol ablation ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
